Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.44 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7712510 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2LMNATSHRGAAHTT | |
| Trifluoroacetic Acid SCHEMBL975654 | 0.94 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNATSHRGAAHTT | |
| SCHEMBL12921313 | 0.93 | TUBB4A (0.40) | SMN1; SMN2LMNATSHRGAAHTT | |
| SCHEMBL8054262 | 0.91 | PPARA (0.42) | SMN1; SMN2LMNATSHRGAAHTT | |
| SCHEMBL975655 | 0.88 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNATSHRGAAHTT | |
| SCHEMBL10266952 | 0.86 | CCR5 (0.32) | EPHX2 | |
| SCHEMBL373806 | 0.86 | TP53 (0.32) | SMN1; SMN2LMNAKDM4EALDH1A1 | |
| SCHEMBL17180853 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNATSHRGAAHTT | |
| SCHEMBL8060081 | 0.85 | GPR119 (0.36) | CNR2CYP3A4CYP2C19EPHX2KCNH2 | |
| SCHEMBL8054741 | 0.83 | CNR2 (0.40) | SMN1; SMN2LMNATSHRGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400962-B1 | Medicinal combinations containing PDE4 inhibitors and NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-08 | — | — | EP | claimed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | claimed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | claimed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | claimed |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-14 | — | — | US | claimed |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | claimed |
| EP-2400962-B1 | Medicinal combinations containing PDE4 inhibitors and NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-08 | — | — | EP | disclosed |
| EP-2555774-B1 | Medicine combinations containing pde4 inhibitors and ep4 receptor antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-10-21 | — | — | EP | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-9161927-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-10-20 | — | — | US | disclosed |
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-27 | — | — | US | disclosed |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| EP-2400962-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2380891-A1 | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010097334-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350035-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR- ANTAGONISTS | PTGER4, PTGER1, PDE4A | SMN1; SMN2 4444/4885LMNA 4688/4885TSHR 1037/4885 |
| US-20130225609-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PDE4A | SMN1; SMN2 4444/4885LMNA 4688/4885TSHR 1037/4885 |
| US-20120035143-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PDE4A, PDE12, PDE3B | SMN1; SMN2 2246/4885LMNA 4610/4885TSHR 2622/4885 |
| US-20140228286-A1 | SPECIFIC PDE4B-INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | PDE4B, PDE3B, PDE4A | SMN1; SMN2 2294/4885LMNA 3583/4885TSHR 1817/4885 |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | SMN1; SMN2 338/4885LMNA 4790/4885TSHR 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.